These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 26254420)

  • 1. Computational genomic analysis of PARK7 interactome reveals high BBS1 gene expression as a prognostic factor favoring survival in malignant pleural mesothelioma.
    Vavougios GD; Solenov EI; Hatzoglou C; Baturina GS; Katkova LE; Molyvdas PA; Gourgoulianis KI; Zarogiannis SG
    Am J Physiol Lung Cell Mol Physiol; 2015 Oct; 309(7):L677-86. PubMed ID: 26254420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel candidate genes of the PARK7 interactome as mediators of apoptosis and acetylation in multiple sclerosis: An in silico analysis.
    Vavougios GD; Zarogiannis SG; Krogfelt KA; Gourgoulianis K; Mitsikostas DD; Hadjigeorgiou G
    Mult Scler Relat Disord; 2018 Jan; 19():8-14. PubMed ID: 29100048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
    Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B
    J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
    Cheng YY; Wright CM; Kirschner MB; Williams M; Sarun KH; Sytnyk V; Leshchynska I; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; van Zandwijk N; Lin RC; Reid G
    Mol Cancer; 2016 Jun; 15(1):44. PubMed ID: 27245839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KIAA0101 in Malignant Pleural Mesothelioma: A Potential Diagnostic and Prognostic Marker.
    Lin P; Zhao Y; Li X; Liang Z
    Comb Chem High Throughput Screen; 2022; 25(9):1498-1506. PubMed ID: 34238152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of genes and pathways involved in malignant pleural mesothelioma using bioinformatics methods.
    Liu X; Qian K; Lu G; Chen P; Zhang Y
    BMC Med Genomics; 2021 Apr; 14(1):104. PubMed ID: 33849532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma.
    Gordon GJ; Mani M; Mukhopadhyay L; Dong L; Edenfield HR; Glickman JN; Yeap BY; Sugarbaker DJ; Bueno R
    J Pathol; 2007 Mar; 211(4):447-54. PubMed ID: 17253596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma.
    Gordon GJ; Mani M; Mukhopadhyay L; Dong L; Yeap BY; Sugarbaker DJ; Bueno R
    J Pathol; 2007 Mar; 211(4):439-46. PubMed ID: 17253597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genes and Pathways Involved in the Progression of Malignant Pleural Mesothelioma: A Meta-analysis of Genome-Wide Expression Studies.
    Mejia-Garcia A; Bonilla DA; Ramirez CM; Escobar-Díaz FA; Combita AL; Forero DA; Orozco C
    Biochem Genet; 2024 Feb; 62(1):352-370. PubMed ID: 37347449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Silico Transcriptomic Analysis of Wound-Healing-Associated Genes in Malignant Pleural Mesothelioma.
    Rouka E; Beltsios E; Goundaroulis D; Vavougios GD; Solenov EI; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
    Medicina (Kaunas); 2019 Jun; 55(6):. PubMed ID: 31212858
    [No Abstract]   [Full Text] [Related]  

  • 11. Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets.
    Ramírez-Salazar EG; Salinas-Silva LC; Vázquez-Manríquez ME; Gayosso-Gómez LV; Negrete-Garcia MC; Ramírez-Rodriguez SL; Chávez R; Zenteno E; Santillán P; Kelly-García J; Ortiz-Quintero B
    Exp Mol Pathol; 2014 Dec; 97(3):375-85. PubMed ID: 25236577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.
    Walter RF; Mairinger FD; Ting S; Vollbrecht C; Mairinger T; Theegarten D; Christoph DC; Schmid KW; Wohlschlaeger J
    Br J Cancer; 2015 Mar; 112(5):883-90. PubMed ID: 25668009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinesin family members KIF11 and KIF23 as potential therapeutic targets in malignant pleural mesothelioma.
    Kato T; Lee D; Wu L; Patel P; Young AJ; Wada H; Hu HP; Ujiie H; Kaji M; Kano S; Matsuge S; Domen H; Kaga K; Matsui Y; Kanno H; Hatanaka Y; Hatanaka KC; Matsuno Y; de Perrot M; Yasufuku K
    Int J Oncol; 2016 Aug; 49(2):448-56. PubMed ID: 27279560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.
    Tian K; Bakker E; Hussain M; Guazzelli A; Alhebshi H; Meysami P; Demonacos C; Schwartz JM; Mutti L; Krstic-Demonacos M
    J Transl Med; 2018 Oct; 16(1):282. PubMed ID: 30316293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma.
    Aoe K; Amatya VJ; Fujimoto N; Ohnuma K; Hosono O; Hiraki A; Fujii M; Yamada T; Dang NH; Takeshima Y; Inai K; Kishimoto T; Morimoto C
    Clin Cancer Res; 2012 Mar; 18(5):1447-56. PubMed ID: 22261805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients.
    Bahnassy AA; Zekri AR; Abou-Bakr AA; El-Deftar MM; El-Bastawisy A; Sakr MA; El-Sherif GM; Gaafar RM
    Exp Mol Pathol; 2012 Aug; 93(1):154-61. PubMed ID: 22504106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profile of aquaporin 1 and associated interactors in malignant pleural mesothelioma.
    Jagirdar R; Solenov EI; Hatzoglou C; Molyvdas PA; Gourgoulianis KI; Zarogiannis SG
    Gene; 2013 Mar; 517(1):99-105. PubMed ID: 23313295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression status of candidate genes in mesothelioma tissues and cell lines.
    Melaiu O; Melissari E; Mutti L; Bracci E; De Santi C; Iofrida C; Di Russo M; Cristaudo A; Bonotti A; Cipollini M; Garritano SI; Foddis R; Lucchi M; Pellegrini S; Gemignani F; Landi S
    Mutat Res; 2015 Jan; 771():6-12. PubMed ID: 25771974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM).
    Cedrés S; Montero MA; Martinez P; Martinez A; Rodríguez-Freixinós V; Torrejon D; Gabaldon A; Salcedo M; Ramon Y Cajal S; Felip E
    Lung Cancer; 2012 Jul; 77(1):192-8. PubMed ID: 22459204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant Pleural Mesothelioma Interactome with 364 Novel Protein-Protein Interactions.
    Karunakaran KB; Yanamala N; Boyce G; Becich MJ; Ganapathiraju MK
    Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.